Clinical trial · Observational
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
NCT00349830CI-TRIAL-00102863recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood draw | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Biomarkers for disease
- timeFrame
- Day one
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
1. Age \> or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled. 2. Prior diagnosis of cancer or suspected of having cancer 3. Karnofsky performance status of greater than 70 4. Standard pretreatment evaluation 5. Signed Stanford University Human Subjects Committee consent
References
Publications (0)
Data not yet available
No reference posted for this study.